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Background: Berberine is a natural alkaloid derived from a traditional Chinese herbal medicine. It is known to
modulate microRNA (miRNA) levels, although the mechanism for this action is unknown. Here, we previously
demonstrate that the expression of 87 miRNAs is differentially affected by berberine in multiple myeloma cells. Among 49
miRNAs that are down-regulated, nine act as oncomirs, including miR-21. Integrative analysis showed that 28 of the
down-regulated miRNAs participate in tumor protein p53 (TP53) signaling and other cancer pathways. miR-21 is involved
in all these pathways, and is one of the most important oncomirs to be affected by berberine in multiple myeloma cells.
Results: We confirmed that berberine down-regulated miRNA-21 expression and significantly up-regulated the
expression of programmed cell death 4 (PDCD4), a predicted miR-21 target. Luciferase reporter assays confirmed that
PDCD4 was directly regulated by miR-21. Bioinformatic analysis revealed that the miR-21 promoter can be targeted by
signal transducer and activator of transcription 3 (STAT3). Down-regulation of interleukin 6 (IL6) by berberine might lead
to inhibition of miR-21 transcription through STAT3 down-regulation in multiple myeloma. Furthermore, both berberine
and seed-targeting anti-miR-21 oligonucleotide induced apoptosis, G2-phase cell cycle arrest and colony inhibition in
multiple myeloma cell lines. Depletion of PDCD4 by short interfering RNA could rescue berberine-induced cytotoxicity in
multiple myeloma cells.
Conclusions: Our results suggest that berberine suppresses multiple myeloma cell growth, at least in part, by
down-regulating miR-21 levels possibly through IL6/STAT3. This led to increased PDCD4 expression, which is likely
to result in suppression of the p53 signaling pathway. These findings may also provide new mechanistic insight
into the anti-cancer effects of certain compounds in traditional Chinese herbal medicines.
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Multiple myeloma (MM) is a clonal B cell malignancy
characterized by proliferation of plasma cells (PCs) within
the bone marrow (BM). Globally, its incidence varies from
1 per 100,000 people in China to about 4 per 100,000
people in most developed countries [1,2]. MM is charac-
terized by profound genomic instability involving both* Correspondence: efeijia@163.com
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potential prognostic relevance [1,2]. Nearly half of MM
tumors are hyperdiploid (HD) with multiple trisomies
of non-random odd-numbered chromosomes, a low
prevalence of chromosomal translocations involving the
immunoglobulin heavy chain (IgH) locus at 14q32 and
chromosome 13 deletion [3]. It has been suggested that
chromosomal abnormalities and other types of genetic or
epigenetic alterations might contribute to miRNA deregu-
lation in cancer [4-6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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non-coding small RNAs that regulate gene expression
through degrading target mRNAs and/or suppressing their
translation by binding to the 3′-untranslated region (3′-
UTR) of target genes. Bioinformatic predictions indicate
that 30% of all human genes are regulated by miRNAs.
Thus, miRNAs are involved in a variety of biological pro-
cesses, from development and differentiation to survival,
apoptosis, and senescence [7-9].
Accumulating evidence suggests that miRNAs that are
significantly over-expressed in tumors may be a novel class
of oncogene. Termed “oncomirs”, these oncogene miRNAs
usually promote tumor development by negatively regulat-
ing tumor suppressor genes that control various biological
processes. Therefore, altering oncomir expression might be
a valuable strategy for cancer treatment [10,11].
Differential miRNA expression and high levels of onco-
mirs, including miR-21, miR-155, miR-17-92, and miR-
125b, have been reported in MM. miR-21 is frequently
over-expressed in MM and is involved in proliferation,
apoptosis, cell cycle, drug-resistance, and pathogenesis
[6,12-15]. Loffler et al. demonstrated that interleukin-6
(IL6) regulates miR-21 transcription in IL6-dependent hu-
man myeloma cell lines (HMCLs) through a signal trans-
ducer and activator of transcription 3 (STAT3)-related
mechanism. Importantly, ectopic expression of miR-21
was sufficient to sustain growth of IL6-dependent MM
cells in the absence of IL6 [16]. This evidence indicates
that miR-21 is an important oncomir in MM.
Berberine (BB), an alkaloid that was initially isolated from
Chinese herbs, is currently used as a traditional medicine to
treat diarrhea caused by bacteria, although the mechanism
for this action is unknown. Accumulating evidence suggests
that BB also elicits anti-cancer effects by inhibiting cell
growth and inducing apoptosis in a variety of cancer cell
lines [17-20]. Animal studies have shown that BB can in-
hibit chemical-induced carcinogenesis, tumor promotion,
and tumor invasion [21,22]. Recent studies also show that
BB exerts anti-cancer effects by inhibiting proliferation and
reproduction of certain tumorigenic microorganisms and
viruses, such as Helicobacter pylori and hepatitis B. BB can
also regulate the transcription of some oncogenes and
carcinogenesis-related genes via interactions with DNA and
RNA. Furthermore, BB is a broad-spectrum enzyme inhibi-
tor that affects N-acetyltransferase, cyclooxygenase-2, and
topoisomerase activities, as well as gene expression and
protein synthesis [23]. Thus, BB can regulate many onco-
genic mRNAs and proteins. However, whether BB can
regulate miRNAs remains unknown.
miRNAs in animals have a highly conserved 5′-end se-
quence consisting of 7–8 nt called the seed sequence. The
seed sequence binds with 100% complementarity to the
target mRNA and is a key feature in the recognition be-
tween a miRNA and its target mRNA [24]. Inhibition ofthe seed sequence leads to a loss of mature miRNA func-
tion, and is the target of anti-miRNA oligonucleotides
(AMOs) [25,26].
In this research, we performed microarray analysis to
explore the possibility that BB regulates miRNA expres-
sion. Our results show that BB differentially regulates the
expression of a number of miRNAs. Forty-nine miRNAs
were down-regulated, of which 28 were shown by KEGG
analysis to be involved in p53 signaling, the cell cycle and
other cancer pathways. Of the 49 miRNAs, miR-21 had
the most target genes and participates in all the signaling
pathways and can, therefore, be considered as one of the
most important oncomirs. The role of miR-21 in MM was
further investigated with the use of AMO-miR-21. Our
findings provide new insight into anti-cancer mechanisms
of traditional Chinese herbal medicines and provide evi-
dence that they are effective in treating cancer.
Methods
Microarray analysis of miRNA expression
Based on our preliminary study, the MM cell line, RPMI-
8266, was treated with 75 μM BB for 48 h. Total miRNA
from 1 × 108 cells was isolated and labeled using an mir-
VANA™ miRNA Isolation kit and mirVANA™ miRNA la-
beling kit (Ambion, Austin, TX, USA).. Samples (4 μg)
labeled with Cy3/Cy5 were hybridized on miRNA microar-
rays (CSC-GE-3, chipscreen biosciences, Shenzhen, China).
After air drying, each chip was scanned with a Generation
III array scanner (Amersham Pharmacia). Data analyses
were performed using Imagequant 5.0 (Array Vision 6.0).
Bioinformatic analysis
miRFocus software (http://mirfocus.org), developed by LC
Science USA, was used to analyze miRNA-target gene
pathways and to determine related miRNA annotations
(Additional file 1: Figure S1).
Oligonucleotides
An anti-miR-21 oligonucleotide (AMO-miR-21) was de-
signed according to sequence complementary to mature
miRNA-21: AMO-miR-21, 5′-ATAAGCTA-3′ (8 bp). A
control scramble AMO (SCR) 5′ -TCATACTA-3′ (8 bp)
was also synthesized (Additional file 1: Figure S2). All oligo-
deoxynucleotides were chemically synthesized and modified
with phosphorothioate and/or fluorescein isothiocyanate
(FITC) by the Shanghai Sangon Bio-engineering Company,
China. The siRNA sequence of PDCD4 (siPDCD4) was
5′-AAGGUGGCUGGAACAUCUAUU-3′. The RNA du-
plexes were synthesized and purified by Shanghai Gene-
Pharma Company, China.
Cell lines, transfection and cell culture reagents
MM cell lines (RPMI-8266 and U226) were obtained
from the Shanghai Institute of Cell Biology, China. The
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10% fetal bovine serum (FBS), 0.05 mM 2-mercaptoethanol,
1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL
penicillin, and 50 U/mL streptomycin. The cells were grown
in RPMI-1640 medium containing 10% fetal calf serum
(FCS) at 37°C in a 5% CO2 humidified atmosphere (Thermo
FORMA 3110).
BB was purchased from Sigma-Aldrich. RPMI-8266 and
U226 cells in the exponential phase of growth were seeded
in 96- or 24-well plates (Costar) and transfected with
0.5 μM AMO-miR-21 using Lipofectamine 2000 (Invitro-
gen) in serum-free RPMI-1640. PDCD4 siRNA and con-
trol SCR (100 nM) were transfected into RPMI-8266 and
U226 cells using Lipofectamine 2000 according to the
manufacturer’s instructions.
Luciferase reporter assays
The full-length human PDCD4 3′-UTR (1917 bp) was PCR-
amplified from cDNA with the following primers: 5′-c
cgctcgagATATAAGAACTCTTGCAGTCT-3′ and 5′-ataaga
atgcggccgcACAGAGGATCTTTACATGTTTA-3′ containing
NotI and XhoI restriction site overhangs, respectively (in-
dicated in italic type). The amplified product, which con-
tains one putative miR-21 binding site, was cloned into
psiCHECK-2 (Promega) immediately downstream of the
Renilla luciferase reporter gene and was named PDCD4 3′-
UTR. Site-directed mutagenesis was performed using the
QuikChange II XL site-directed mutagenesis kit (Strata-
gene) to change three nucleotides in the seed sequence, in
which ATAAGCTA was substituted by TAGCTACT. The
mutant plasmid was named PDCD4-mut- 3′-UTR.
RPMI-8266 cells were cotransfected with 100 nM miR-21
or 0.5 μM AMO-miR-21 together with PDCD4 3′-UTR or
PDCD4-mut-UTR and assayed for luciferase activity 24 h
post-transfection using the Dual-Luciferase Reporter Assay
System (E1910, Promega). For each sample, firefly luciferase
activity was normalized against Renilla luciferase activity.
Real-time PCR assay
RPMI-8266 and U226 cells were treated with 75 μM
and 120 μM BB, respectively. Total RNA was extracted
in TRIzol (Invitrogen). The levels of miR-21 and U6
small nuclear RNA (snRNA) were determined using a
miRNA RT-PCR Quantitation Kit (Shang Hai Gene
Pharma Company). U6 snRNA was used as the internal
control, and the fold-change in miR-21 expression was
calculated using the 2−ΔΔCT method.
RPMI-8266 cells were transfected with 0.5 μM AMO-
miR-21 using Lipofectamine 2000 and cultured for 48 h.
Levels of PDCD4 mRNA were determined using SYBR-
Green real-time PCR assays. PDCD4 primers used were
5′-CCAAAGAAAGGTGGTGCA-3′ and 5′-TGAGGTAC
TTCCAGTTCC-3′ and GAPDH primers were 5′-CAA
CGGATTTGGTCGTATT-3′ and 5′-CACAGTCTTCTGGGTGGC-3′. PDCD4 mRNA levels were normalized to
those of GAPDH.Western blot analysis and enzyme-linked immunosorbent
assay (ELISA)
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer in the presence of proteinase inhibitor (Biocolor Bio-
Science & Technology Company, Shanghai, China). Cell ly-
sates (30 μg) were denatured in Laemmli sample buffer
(Bio-Rad) for 5 min at 95.1°C, separated by 10% SDS-PAGE
and transferred to nitrocellulose membranes. Membranes
were blocked with 5% (w/v) fat-free milk in phosphate-
buffered saline (PBS) and 0.5% (v/v) Tween-20 for 1 h, and
then incubated with anti-PDCD4 antibody (Cell Signaling
Technology) at room temperature for 2 h. After washing,
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody. Signals were visualized
with enhanced chemiluminescence (ECL) (BeyoECL Plus,
Beyotime), and analyzed using a BI-2000 system (Beyo-
time, Haimen, Jiangsu province, China),.
RPMI-8266 and U226 cells were treated with 75 μM
and 120 μM BB, respectively.
IL6 protein levels in supernatants were determined
using a human IL6 ELISA kit (R&D Systems).MTT assay
RPMI-8266 cell viability was determined by 3-(4,5-dimeth-
ylthiazol-2-yl)-2,4- diphenyl-tetrazolium bromide (MTT)
assays. Briefly, cells were seeded at a density of 1 × 105
cells/ml in 96-well plates (100 μl/well). The cells were
treated with BB (75 μM) or AMO-miR-21 (0.5 μM). At
48 h post-treatment, 20 μl MTT stock solution (5 mg/ml)
was added to each well, and the plate was incubated for
4 h at 37°C. The media was then removed, and dimethyl
sulfoxide (DMSO) (150 μl) was added to dissolve the blue
formazan crystals produced by viable cells. Cell viability
was assessed by measuring the absorbance at 570 nm on a
Bio-Rad microtiter plate reader.Colony assay
The colony assay for dispersed single cells was performed
to measure the capacity of cells to form colonies. Cells
treated with BB (75 μM) or AMO-miR-21 (0.5 μM) were
seeded onto a 24-well plate (2 × 103 cells per well) and
mixed thoroughly with 0.9% methylcellulose solution in
RPMI-1640 containing 20% FBS. Single cells were ran-
domly and evenly distributed throughout each well.
Colonies were formed during incubation for 1–2 weeks
at 37°C in a 5% CO2 humidified atmosphere. Light mi-
croscopy was used to observe and count colonies con-
taining more than 50 cells.
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Flow cytometry (Coulter Elite; Fullerton, CA, USA) was
performed to analyze cell cycle profiles and levels of apop-
tosis. For cell cycle analysis, cells were collected, rinsed
twice with PBS, fixed in 70% ethanol for 1 h at 4°C and
stained with propidium iodide (PI) solution (50 μg/ml)
containing RNAse A (200 ug/ml). Cell cycle was analyzed
using flow cytometry according to DNA content. To
analyze apoptosis, cells were stained with fluorescein iso-
thiocyanate (FITC)-conjugated annexin V and PI. For each
sample, data from approximately 10,000 cells were re-
corded in the list mode on logarithmic scales. Apoptotic
and necrotic cells were analyzed by performing quadrant
statistics on PI-negative/annexin V-positive cells and PI/
annexin V double-positive cells, respectively.
Results
BB modulates miRNA expression in MM cells
Of the 1152 miRNAs represented on the microarray, 87
were differentially expressed between BB-treated and con-
trol cells (Additional file 1: Figure S3); 49 were down-
regulated, and 38 were up-regulated compared to control.
Further analysis revealed that nine of the 49 down-
regulated miRNAs were potential oncomirs, and three of
the 38 up-regulated miRNAs are considered tumor sup-
pressor genes (Additional file 2: Table S1 and Additional
file 2: Table S2). Among the 49 down-regulated miRNAs,
mirFocus software identified 28 that are involved in p53 sig-
naling, the cell cycle and other cancer pathways (Figure 1).
Of these, miR-21, has the most identified target genes and
participates in all the above signaling pathways. Thus mir-
21 can be considered as one of the most importantFigure 1 Ingenuity analysis of miRNA predictive pathways. Among the
involved in p53 signaling, cell cycle and other cancer pathways. miR-21 pa
as one of the most important oncomirs in the effects of BB on MM.oncomirs. These results suggest that BB suppression of
MM might involve miRNA-mediated gene expression.
Regulation of miRNA-21, IL6 and PDCD4 levels by berberine
and the effects of exogenous IL6 on miRNA-21 expression
in MM cells
To validate down-regulation of miR-21 by BB and to inves-
tigate the effect of exogenous IL6 on BB-modulated
miRNA-21 expression in MM, RPMI-8266 and U226 cells
were treated without or with 75 μM or 120 μM BB, respect-
ively, in the absence or presence of IL6 (0.5 ng/ml). Total
RNA and/or protein was isolated and analyzed for the ex-
pression of miR-21 and PDCD4 using real-time PCR and
western blot analyses. As shown in Figure 1, BB treatment
significantly down-regulated miR-21 levels in a dose-
dependent manner, and exogenous IL6 somewhat rescued
BB-mediated down-regulation of miR-21 (Figure 2A). Inter-
estingly, BB also reduced the level of IL6 in supernatant
(Figure 2B). IL6 is an important oncogene in MM and is
involved in miR-21 transcription [16]. These results con-
firmed that BB down-regulates miR-21 and IL6 and conse-
quently the miRNA target gene, PDCD4 was up-regulated
(Figure 2C, 2D). Meanwhile, exogenous IL6 could rescue
BB-induced miRNA-21 down-regulation in MM cells.
BB down-regulates STAT3 mRNA levels in MM cells
Bioinformatic analysis showed that sequence upstream
of the miR-21 gene contained two putative STAT3 bind-
ing sites (Additional file 1: Figure S4A). To investigate
whether BB affects STAT3 mRNA levels, RPMI-8266
and U226 cells were treated with 75 μM and 120 μM
BB, respectively. STAT3 mRNA levels were significantly49 down-regulated miRNAs, 28 were shown by mirFocus to be
rticipates in all the above signaling pathways, and can be considered
Figure 2 Effect of BB on levels of miRNA-21, IL6, and PDCD4 and the effect of exogenous IL6 on BB-induced miRNA-21 expression.
RPMI-8266 and U226 cells were treated with 75 μM and 120 μM BB, respectively, in the absence or presence of IL6 (0.5 ng/ml) and harvested
48 h after treatment. Total RNA and protein were isolated and analyzed for levels of miRNA-21 and PDCD4. (A) miR-21 and U6 snRNA levels
were determined by quantitative real-time PCR in the absence or presence of IL6. (B) The IL6 protein levels in supernatants were determined
using an ELISA kit. (C) Relative PDCD4 mRNA levels were measured with SYBR-Green real-time PCR. (D) PDCD4 protein levels were assessed by
western blot analysis. *p < 0.01 vs. control. The data show that BB significantly down-regulated miR-21 and IL6 levels in RPMI-8266 and U226 cells and
up-regulated PDCD4 mRNA and protein levels in 8266 cells. Notably, exogenous IL6 could attenuate the reduction in miRNA-21 expression induced by BB.
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cruited to the miR-21 regulatory region in response to
IL6 [16]; therefore, BB-mediated down-regulation of IL6
might cause transcriptional inhibition of miR-21 via re-
duced STAT3 action.
PDCD4 is a direct target of miRNA-21
Because BB treatment reduced miRNA-21 levels in MM
cells, we next examined whether BB also regulated the ex-
pression of genes targeted by miRNA-21. We first focused
on the PDCD4 gene, which is known to be targeted by
miR-21. AMO-miR-21 was transfected into RPMI-8266
cells to knock down endogenous mir-21. As shown in
Additional file 1: Figure S5A and S5B, PDCD4 mRNA and
protein levels were significantly increased in AMO-miR-
21-transfected cells compared with control-transfected
cells, suggesting that PDCD4 is regulated by miR-21.
We performed luciferase reporter assays to determine
whether PDCD4 is a direct target of miR-21. The luciferase
reporter plasmid containing the 3′-UTR of PDCD4(PDCD4-3′UTR) or a mutant PDCD4 3′-UTR contain-
ing a mutation in the putative miR-21 binding site
(PDCD4-mut-3′UTR) were co-transfected with AMO-
miR-21 or a miRNA-21 mimic. The firefly luciferase
plasmid was used as an internal control. As shown in
Additional file 1: Figure S5C, over-expression of the
miR-21 mimic significantly suppressed luciferase activ-
ity, whereas transfection of AMO-miR-21 significantly
increased luciferase activity in cells transfected with
PDCD4-3′UTR. In contrast, luciferase activities in cells
transfected with PDCD4-mut-3′UTR were not significantly
changed by either over-expression or knockdown of miR-
21 (Additional file 1: Figure S5C,S5D). These results indi-
cate that PDCD4 might be a direct target of miR-21.
Transfection efficiency and localization of AMO-mir-21 in
RPMI-8266
AMO-mir-21 was modified with FITC, and transfected into
RPMI-8266 cells using Lipofectamine 2000. High levels of
AMO-mir-21-FITC were detected, mainly in the cytoplasm
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at 24 h and 48 h post-transfection 95.27% and 85.8% of
cells, respectively, were FITC-positive (Additional file 1:
Figure S6B).
BB and AMO-miR-21 inhibit cell growth and induce apoptosis
To determine the effects of BB on MM cell growth via
miR-21, RPMI-8266 cells were treated with BB (75 μM) or
AMO-miR-21 (0.5 μM) as described in Materials and
Methods. Cell viability was assessed by triplicate MTT as-
says. As shown in Figure 3A, treatment with BB at 50 μMFigure 3 BB and AMO-miR-21 inhibit cell viability and induce apopto
various concentrations of BB and AMO-miR-21 then plated in 96-well plates in m
was assessed by triplicate MTT assays. (A) BB and AMO-miR-21. *p < 0.01 vs. bla
in a dose-dependent manner. RPMI-8266 cells were treated with 75 μM BB or 0
V and PI for 15 min., and then analyzed by flow cytometry. (B) Both BB and AM
*p < 0.01 vs. control. (C) Both BB and AMO-miR-21 significantly induced G2-phaor higher significantly inhibited cell proliferation. Similar
results were also observed when miR-21 was knocked
down by AMO-miR-21 (Figure 3A), and these effects were
dose-dependent. Thus, both BB and AMO-miR-21 inhib-
ited MM cell viability, indicating that the BB-mediated cell
death might involve miR-21 down-regulation.
We next investigated whether BB treatment or miR-21
inhibition could induce apoptosis in MM cells. To this
end, RPMI-8266 cells were treated with BB or transfected
with AMO-miR-21. The cells were then stained with
annexin V and PI and analyzed by flow cytometry. Assis and G2 phase cell cycle arrest. RPMI-8266 cells were treated with
edium containing 10% FCS and cultured for another 48 h. Cell viability
nk and Scramble controls. Both BB and AMO-miR-21 inhibited cell viability
.5 μM AMO-miR-21. Cells were then stained with FITC-conjugated annexin
O-miR-21 promoted apoptosis and IL6 could reduce BB-induced apoptosis.
se cell cycle arrest. *p < 0.01 vs. blank or SCR controls.
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treatments significantly increased the number of apoptotic
cells, indicating that BB treatment and miR-21 inhibition
induce apoptosis.
BB and AMO-miR-21 induce G2-phase cell cycle arrest
To investigate the effect of BB treatment or miR-21 inhib-
ition on the cell cycle, RPMI-8266 cells were treated with
BB or transfected with AMO-miR-21 and then subjected to
cell cycle analysis by flow cytometry. As shown in Figure 3C
and Additional file 1: Figure S8, BB treatment resulted in
an accumulation of cells in the G2/M phase. Interestingly,
miR-21 inhibition by AMO-miR-21 produced almost iden-
tical effects on the cell cycle to those observed following BB
treatment. These results indicate that BB-induced G2/M ar-
rest in MM cells is at least partially mediated via miR-21
down-regulation.
BB and AMO-miR-21 suppress colony formation
Colony growth is closely related to neoplastic capacity. To
investigate the effect of BB and AMO-miR-21 on colony
formation in RPMI-8266 cells, colony growth assays were
performed. One week post-treatment, we found that
RPMI-8266 cells treated with AMO-miR-21 or BB showed
fewer colonies, compared to the control groups (Figure 4).
These results indicate that both BB and miR-21 knock-
down had an inhibitory effect on the malignant growth
capacity of MM cells.
Testing siRNAs for their ability to silence PDCD4
To examine whether miR-21 down-regulation is associ-
ated with BB-induced cytotoxicity, we further studiedBlank     SCR     
(A) 10
(B)
Figure 4 BB and AMO-miR-21 suppress colony formation. Colony grow
(A) Images of representative colony formation. (B) After incubation for 1 w
were observed under a light microscope and the number of colonies counthe effect of PDCD4 knockdown in MM cells. We de-
signed three siRNAs against the PDCD4 gene and evalu-
ated their knockdown efficiency using real-time PCR
analysis. We found that one siRNA efficiently knocked
down PDCD4 mRNA and down-regulated PDCD4 pro-
tein levels in RPMI-8266 cells (Figure 5A,B).
PDCD4 siRNA ameliorates berberine-induced inhibition of
MM cell growth
Next, we examined whether PDCD4 knockdown could res-
cue the cytotoxic effect of BB treatment. RPMI-8266 and
U226 cells transfected with PDCD4 or control siRNA were
treated with BB for 72 h, and cell viability was assessed by
MTT assays. As shown in Figure 5C,D, PDCD4 siRNA
transfection alone did not affect cell viability. However,
PDCD4 depletion significantly ameliorated BB-induced
growth inhibition, indicating that PDCD4 could be a down-
stream effector protein in the BB-induced cell growth in-
hibition pathway, and that it might be a tumor suppressor
in MM cells.
Discussion
Traditional Chinese medicine is an inexpensive treat-
ment strategy. However, for most treatments neither the
underlying therapeutic mechanisms nor the molecular
targets of active compounds are well defined. Here, we
describe a mechanism in MM cells by which BB inhibits
cell proliferation and induces apoptosis and cell cycle ar-
rest (Figure 3) via the regulation of miR-21 (Figure 2A).
miR-21 is over-expressed in the vast majority of cancer
types analyzed so far and is thus recognized as an import-
ant oncomir [27,28]. Inhibition of miR-21 suppressed cellAMO-miR-21 BB
th capacity was assessed by methylcellulose colony formation assays.
eek, RPMI-8266 cells treated with 75 μM BB or 0.5 μM AMO-miR-21
ted. Three independent experiments were carried out.
Figure 5 siRNA down-regulation of PDCD4 expression and rescue of BB-induced growth inhibition. RPMI-8266 cells were treated with 100
nM PDCD4 siRNA for 6 h, and harvested 48 h after treatment. Total RNA and protein were isolated and analyzed for PDCD4 expression levels. (A)
PDCD4 mRNA levels were determined by SYBR-Green real-time PCR. (B) PDCD4 protein levels were determined by western blot analysis. PDCD4
siRNA significantly down-regulated PDCD4 levels in RPMI-8266 cells. *p < 0.01, vs. control. RPMI-8266 and U226 cells were pre-treated as above
and then plated in 96-well plates in medium containing 10% FCS for a further 72 h in the presence of BB (75 μM). Cell viability was assessed by
triplicate MTT assays. The results indicate that PDCD4 siRNA can rescue BB-induced growth inhibition. (C) RPMI-8266 cells. (D) U226 cells.
*p < 0.01 vs. control.
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model [29]. Recently, Medina et al. demonstrated that miR-
21 over-expression leads to a pre-B malignant lymphoid-
like phenotype and that inhibiting miR-21 alone induces
complete tumor regression in a few days, suggesting that
miR-21 is a central oncomiR in tumor formation [30].
Interestingly, MM is also a B cell neoplasm of clonal malig-
nant cells in the bone marrow. Another group has also sug-
gested that miR-21 as a key oncomiR in MM [29].
Our results show that BB down-regulates miR-21 levels
in MM cell lines (RPMI-8266 and U226) (Figure 2A), but
does not affect miR-21 levels in IL6-independent human
myeloid leukemia cells (HL60, NB4, and K562 cell lines;
data not shown).
Bioinformatic analysis identified two putative STAT3
binding sites upstream of the miR-21 gene (Additional file 1:
Figure S4A), and STAT3 mRNA levels were significantly de-
creased by BB (Additional file 1: Figure S4B). STAT3 has
been validated to be recruited to the miR-21 regulatory re-
gion in response to IL6 [16]. Our data indicate that IL6levels in cell supernatants were significantly reduced by BB.
Exogenous IL6 could partly ameliorate BB-mediated miR-
21 down-regulation (Figure 2A). Thus, in MM, down-
regulation of IL6 by BB might lead to the inhibition of
miR-21 transcription through STAT3 down-regulation.
Antisense oligonucleotides targeting mRNAs have been
successfully used to identify miRNA functions and for the
development of therapeutic agents [31-33]. As miRNAs are
small nucleic acids (19–24 nt), antisense inhibition is con-
sidered to be the best and possibly the only practical ap-
proach for specific pharmacological inhibition of their
function [31]. Recently, an 8-mer nucleic acid complemen-
tary to the seed region of an miRNA, called a tiny anti-
miRNA, was used to antagonize miRNA function [25,26].
In this study, high levels of AMO-mir-21-FITC were de-
tected by confocal microscopy, mainly in the cytoplasm
(Additional file 1: Figure S6A), and 95.27% of cells were
FITC positive at 24 h post-transfection (Additional file 1:
Figure S6B). Here, we have investigated the anti-MM effects
of AMO-miR-21 and compared them with those of BB.
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(Additional file 1: Figure S5). Like AMO-miR-21, BB treat-
ment down-regulated miR-21 and up-regulated PDCD4.
Intriguingly, BB and AMO-miR-21 produced almost iden-
tical effects on cell proliferation, apoptosis, and cell cycle
profile (Figure 3). Therefore, we conclude that the anti-
MM activity of BB might be achieved, at least in part,
through the inhibition of miR-21/PDCD4 signaling.
The identification of miRNA target genes is necessary to
assess the roles of aberrantly expressed miRNAs in human
cancer and to subsequently develop miRNA-based gene
therapies. miR-21 is strongly up-regulated in a variety of
human neoplastic disorders. It can target and, therefore,
can potentially regulate a number of important tumor sup-
pressor genes (e.g., PDCD4, PTEN, TPM1, SPRY, RECK,
and NFIB), which has attracted the attention of researchers
in various fields [34,35]. PDCD4, a 64 kDa protein, is an
important, recently identified tumor suppressor that in-
hibits cell transformation, translation and invasion. PDCD4
is down-regulated in several types of human cancer
[36-38], and is an independent predictor of poor prognosis
in renal cell carcinoma patients [39]. Consistent with this
notion, we show here that both BB and AMO-miR-21 up-
regulate PDCD4 by suppressing miR-21 (Additional file 1:
Figure S5A-B, Figure 2C-D). Silencing PDCD4 with siRNA
rescued BB-induced cytotoxicity (Figure 5). Furthermore,
PDCD4 modulates the expression of other genes on two
levels. PDCD4 affects transcription of certain genes by
inhibiting the activity of specific transcription factors, such
as c-Jun [40,41], Sp1 [42] and p53 [43]. In addition, PDCD4
is thought to act as a suppressor of translation. A substantial
body of evidence also suggests that PDCD4 is associated
with p53 mRNA and suppresses its translation, thereby
maintaining a low level of p53 in unstressed cells. This sup-
pression is abrogated due to low levels of PDCD4 after
DNA damage [44]. These observations are consistent with
our predictions from the bioinformatic analysis (Figure 1).
Mechanisms of drug-insensitivity or resistance are in-
volved in the apoptotic capacity of cancer cells [45]. Almost
all cytotoxic anti-tumor drugs used clinically exert their ef-
fects by inducing apoptosis [46]. It is known that tumors
escape apoptotic signals by expressing anti-apoptotic pro-
teins, such as Bcl-2 family proteins [45,46]. Our study indi-
cated that, similar to the effect caused by AMO-miR-21
inhibition of miR-21, BB treatment significantly promoted
apoptosis, demonstrating the potential of BB and of target-
ing miR-21 for the treatment of MM (Figure 3). Hu et al.
also show that miR-21 mediates berberine-induced apop-
tosis in human multiple myeloma cells [47].
Conclusions
To the best of our knowledge, our study is the first to
show that the traditional Chinese medicine, BB, modu-
lates the expression profile of many miRNAs in MMcells by down-regulating oncomirs and/or up-regulating
tumor suppressor miRNAs. Our data show that BB treat-
ment of MM cells down-regulated miR-21, probably via in-
hibition of IL6/STAT3, and led to the up-regulation of
PDCD4, which was likely to result in suppression of the p53
signaling pathway. Therefore, BB is a therapeutic candidate
for the treatment of MM (Additional file 1: Figure S10).
Our work also provides new insight into the mechanisms
underlying the anti-cancer effect of a traditional Chinese
herbal medicine.
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